<DOC>
	<DOCNO>NCT00416949</DOCNO>
	<brief_summary>RATIONALE : Radioactive iodine kill thyroid cancer cell give radiation . PURPOSE : This clinical trial study side effect , best dose , well iodine I 131 work treat patient thyroid cancer .</brief_summary>
	<brief_title>Iodine I 131 Treating Patients With Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine relationship estimate absorb dose iodine I 131 tumor response normal organ toxicity different dosimetric measure , use data derive clinical radionuclide therapy study patient thyroid cancer . OUTLINE : Patients receive oral dosimetric iodine I 131 ( ^131I ) day 2 undergo nuclear medicine image 0.5-4 hour , 24 , 48 , 72 hour dosimetric ^131I . Single-photon emission compute tomography ( SPECT ) /CT scan perform 0.5-4 hour 24 48 hour head neck region , include salivary gland . Subsequent SPECT/CT scan perform candidate tumor site . Patients undergo ^131I therapy day 11 . Saliva collect day 1 2 , week 2 4 , month 3 6 measure saliva flow rate . Blood collect baseline periodically study measure FLT3 ligand level . PROJECTED ACCRUAL : A total 96 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis thyroid cancer Measurable disease CT scan nuclear medicine image Eligible , standard care criterion , iodine I 131 therapy PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonbarrier method contraception ( e.g. , combine progesteroneonly oral contraceptive pill , intrauterine device , depot progesterone , stable relationship partner vasectomy ) No malignancy within past 5 year except squamous cell basal cell carcinoma skin No nonthyroidal condition know affect iodine I 131 uptake ( e.g. , New York Heart Association class III IV congestive heart failure renal failure ) No alcoholism drug abuse within past 2 year No severe emotional , behavioral , psychiatric problem would preclude study compliance ( e.g. , severe claustrophobia ) PRIOR CONCURRENT THERAPY : No intravenous watersoluble radiographic contrast within past 4 week No iodinate contrast agent within past 3 month No concurrent drug may affect thyroid renal function ( e.g. , renal drug , lithium , amiodarone , iodinecontaining medication , corticosteroid ) No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage I follicular thyroid cancer</keyword>
	<keyword>stage I papillary thyroid cancer</keyword>
	<keyword>stage II follicular thyroid cancer</keyword>
	<keyword>stage II papillary thyroid cancer</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>stage III papillary thyroid cancer</keyword>
	<keyword>stage IVA follicular thyroid cancer</keyword>
	<keyword>stage IVB follicular thyroid cancer</keyword>
	<keyword>stage IVC follicular thyroid cancer</keyword>
	<keyword>stage IVA papillary thyroid cancer</keyword>
	<keyword>stage IVB papillary thyroid cancer</keyword>
	<keyword>stage IVC papillary thyroid cancer</keyword>
</DOC>